Подписаться
Robert G Maki, MD PhD
Robert G Maki, MD PhD
Professor and Member, Memorial Sloan-Kettering Cancer Center & Weill-Cornell Medical College
Подтвержден адрес электронной почты в домене mskcc.org - Главная страница
Название
Процитировано
Процитировано
Год
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
54912010
A framework for advancing our understanding of cancer-associated fibroblasts
E Sahai, I Astsaturov, E Cukierman, DG DeNardo, M Egeblad, RM Evans, ...
Nature Reviews Cancer 20 (3), 174-186, 2020
28242020
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
RP DeMatteo, KV Ballman, CR Antonescu, RG Maki, PWT Pisters, ...
The lancet 373 (9669), 1097-1104, 2009
17352009
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …
GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ...
The Lancet 381 (9863), 295-302, 2013
15432013
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the …
CD Blanke, C Rankin, GD Demetri, CW Ryan, M Von Mehren, ...
Journal of clinical oncology 26 (4), 626-632, 2008
13642008
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
GD Demetri, M Von Mehren, CR Antonescu, RP DeMatteo, KN Ganjoo, ...
Journal of the National Comprehensive Cancer Network 8 (Suppl_2), S-1-S-41, 2010
13172010
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ...
The Lancet Oncology 18 (11), 1493-1501, 2017
12232017
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
11492011
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines
GD Demetri, RS Benjamin, CD Blanke, JY Blay, P Casali, H Choi, ...
Journal of the National Comprehensive Cancer Network 5 (S2), S-1-S-29, 2007
11312007
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu, P Besmer, T Guo, K Arkun, G Hom, B Koryotowski, ...
Clinical cancer research 11 (11), 4182-4190, 2005
10002005
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
S Gnjatic, D Atanackovic, E Jäger, M Matsuo, A Selvakumar, NK Altorki, ...
Proceedings of the National Academy of Sciences 100 (15), 8862-8867, 2003
9922003
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
MC Heinrich, RG Maki, CL Corless, CR Antonescu, A Harlow, D Griffith, ...
Journal of clinical oncology 26 (33), 5352-5359, 2008
9882008
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ...
New England Journal of Medicine 363 (18), 1727-1733, 2010
9752010
Comprehensive and integrated genomic characterization of adult soft tissue sarcomas
AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ...
Cell 171 (4), 950-965, 2017
8882017
Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized …
GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ...
Journal of Clinical Oncology 34 (8), 786-793, 2016
8672016
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for …
RG Maki, JK Wathen, SR Patel, DA Priebat, SH Okuno, B Samuels, ...
Journal of Clinical Oncology 25 (19), 2755-2763, 2007
8662007
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ...
Journal of Clinical Oncology 20 (12), 2824-2831, 2002
8192002
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ...
The Lancet 387 (10028), 1629-1637, 2016
8152016
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
J Barretina, BS Taylor, S Banerji, AH Ramos, M Lagos-Quintana, ...
Nature genetics 42 (8), 715-721, 2010
8082010
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
RP DeMatteo, JS Gold, L Saran, M Gönen, KH Liau, RG Maki, S Singer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2008
6822008
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20